Actively Recruiting
Reduced-dose Alemtuzumab for Kidney Transplant Rejection
Led by Erasmus Medical Center · Updated on 2024-02-21
25
Participants Needed
1
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prospective, follow-up study of kidney transplant recipients treated with alemtuzumab anti-rejection therapy for severe or glucocorticoid-resistant kidney transplant rejection.
CONDITIONS
Official Title
Reduced-dose Alemtuzumab for Kidney Transplant Rejection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Treatment for severe or glucocorticoid-resistant kidney transplant rejection with alemtuzumab.
You will not qualify if you...
- Treatment with a different lymphocyte depleting agent (e.g. rATG) prior to treatment with alemtuzumab for the same rejection episode.
- Recipients who have T cell counts below 200 �d7 10^6/L before the start of therapy (for instance, because of lymphocyte depleting induction therapies).
- Inability to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Erasmus MC
Rotterdam, South Holland, Netherlands, 3015 GD
Actively Recruiting
Research Team
L
Lukas K van Vugt, Drs.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here